-+ 0.00%
-+ 0.00%
-+ 0.00%
Alto Neuroscience plans to use USD 100 million offering proceeds to expand ALTO-207 Phase 3 program in treatment-resistant depression
Share
Listen to the news
Alto Neuroscience plans to use USD 100 million offering proceeds to expand ALTO-207 Phase 3 program in treatment-resistant depression
  • Alto Neuroscience plans to use new capital to accelerate and expand clinical development of ALTO-207.
  • Funds target an additional planned Phase 3 trial of ALTO-207 as monotherapy for treatment-resistant depression.
  • Proceeds also earmarked for general working capital to support ongoing operations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130747BIZWIRE_USPR_____20260713_BW672035) on July 13, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending